This study is aimed to investigate the methylation level of candidate genes and its impact on thyroid carcinoma (THCA) development. Infinium Human Methyla- 
incidence of thyroid carcinoma is still on the rise for uncertain reasons. Some researchers have supposed that it might be associated with epigenetic events. [3] [4] [5] As THCA recurrence is a common event in thyroid carcinoma patients, especially in the early stage. 6, 7 Therefore, it is imperative to figure out the pathogenesis of THCA for developing effective diagnostic and therapeutic strategies.
DNA methylation is an epigenetic process linked to the regulation of several biological events, including transcriptional regulation of gene expression, X chromosome inactivation, genomic "imprinting," silencing endogenous retroviruses and so forth. 8 The novel therapeutic target. 12 Thus, aberrant promoter methylation may be an effective way to detect candidate targets for THCA treatment.
In recent years, the deeper insights into THCA and the rapid development of molecular detection technology have allowed analyses of THCA at the molecular level. Genome-wide expression analysis has been successfully adopted to identify molecular signatures, improving the diagnosis and prognosis of several types of tumours. 13 Considerable researches have explored the mechanism of certain genes in multiple types of cancers via genome-wide microarray analysis of gene expression profiling. For instance, Hou et al 14 uncovered an epigenetic mechanism that BRAF could promote PTC carcinogenesis through modulating the methylation and the expression of multiple crucial genes. Nikolova et al 15 revealed the significant role of RGS4 in thyroid carcinogenesis and identified molecular targets for THCA treatment through genome-wide gene expression profiles. HORMA-domain containing 2 (HORMAD2) was a conserved meiotic chromosomal protein-coding gene in many organisms, including yeast, plants, nematodes and mammals. 16 Nonetheless, few studies focused on the molecular mechanism of HORMAD2 from the perspective of whole genome DNA methylation and epigenetic regulation of gene expression.
The purpose of present research is to probe into the methylation level of candidate genes and the effects on THCA progression. We first identified differentially expressed genes (DEGs) and relevant
CpG sites via bioinformatics analysis via R programme. Then, DNA methylation level in tumour and normal tissues was detected by methylation-specific PCR (MSP). Subsequently, we observed significantly hypermethylated HORMAD2, of which the expression was examined by qRT-PCR and Western blot. Furthermore, 5 0 -aza-2 0 -deoxycytidine was utilized to investigate the impact on the methylation level of HORMAD2 and biological functions in THCA. 
| MATERIALS AND METHODS

| DNA methylation profiling
| CHARM (comprehensive high-throughput arrays for relative methylation)
Comprehensive high-throughput arrays for relative methylation was applied to McrBC analysis, the array design and computational algorithms are fractionation method-independent and make this a simple, general, relatively inexpensive tool suitable for genome-wide analysis, and in which individual samples can be assayed reliably at very high density, allowing locus-level genome-wide epigenetic discrimination of individuals, not just groups of samples. The process of establishing the array was as follows: (i) all the CpGs in the genome were identified and any region of 300 bp with no CpGs was removed.
(ii)
Probes with multiple matches including fuzzy matches as defined by
NimbleGen were discarded to the genome. (iii) Any region of 300 bp between sequential probes was divided into two new regions, while any region with fewer than 15 probes was removed. (iv) Regions were tiled using 50-mers 35 bp apart.
| Data processing and bioinformatics analysis
The b values, or the percentage of CpGs at a given site that were methylated, were calculated for every sample at each CpG site.
Observations with detection P > .05 were set to missing, and any CpG site with missing data was omitted from the analysis. The R programme, included in the SVA package, was used to adjust for the specific chip. A parametric empirical Bayes framework, that is a particularly robust method for dealing with small samples sizes, was uti- 
| Overall survival analysis
MethSurv performed univariable and multivariable survival analysis based on patient methylation levels for any CpG site (probe) using
Cox proportional hazards models. In the univariable analysis, survival 
| Methylation-specific PCR (MSP)
Bisulfite-treated DNA (50 ng) was mingled with AmpliTaq Gold polymerase (Applied Biosystems), mgCl2, and deoxynucleotide triphosphates for amplified reaction of MSP. The PCR amplification was carried out for 40 cycles at the annealing temperature of 60°C for 30 seconds. The final products were subjected to electrophoresis in a 2% agarose gel, and then recorded using a Molecular Imager (BioRad, Hercules, CA, USA). The methylation-specific primers were listed in Table 2 .
| 5-aza-2
-deoxycytidine treatment
Thyroid cancer cell lines were treated with 5-aza-2 0 -deoxycytidine (Sigma) to demethylate HORMAD2 gene. For demethylation, the cells were cultured in the growth medium, to which 5-aza-2 0 -deoxycytidine was added at a concentration of 2 mmol/L for 3 days before extraction of DNA using the Puregene DNA isolation kit (Gentra Systems Inc., Munich, Germany).
| Western blot
A total of 20 lg proteins were added in 10% sodium dodecyl sul- 
| Flow cytometry analysis
The cell cycle and apoptosis were detected by flow cytometry. For apoptosis, both adherent and non-adherent cells were collected
T A B L E 2 The methylation-specific PCR primers sequence
MF, methylation forward; MR, methylation reverse; UF, unmethylated forward; UR, unmethylated reverse; F, forward; R, reverse.
and rinsed using pre-cooled PBS twice and then resuspended in 
| Transwell assay
The cell mobility and invasiveness were analysed through transwell crystal violet, and counted in high powered fields (10 6 ) with light microscope.
| Wound healing assay
TPC-1 and FTC-133 cells were seeded onto 6-well plates, and linear scratch wounds in the confluent monolayers were created using a pipette tip. Inhibition of cell propagation was observed in medium containing FBS. Wound images at 0, 24 and 36 hours were obtained via a digital camera mounted on light microscope. The wound healing results were analysed using Image J software.
| Tumour formation assay in vivo
Ten BALB/c nude mice (4-5 weeks old, 18-20 g, male) were purchased from Shanghai Experimental Animal Center (Shanghai, China) and randomly divided into 2 groups and labelled. The whole experi- 
| Statistical analysis
The experimental data were analysed by Graphpad 6.0 (Version 6, CA, USA). Results were displayed in form of mean AE standard deviation. Comparison between the two sets of data was performed using Student's t test, while the differences between the three or more data were assessed by One-way ANOVA. All experiments were repeated thrice. P < .05 signified a statistical significance. Figure 1E ). These results indicated that the sample data we used exerted differential methylation level from two endpoints.
| The methylation level of top 1000 differentially methylated CpG sites in imprinted genes
Probes were implemented within the Bioconductor package
ChAMP and relied on a series of objects created using this pack- was correlated with poor prognosis in THCA patients ( Figure 3D ).
Based on the methylation levels, RFS of 54 THCA patients was a continuous variable, which could be considered as prognostic factors. RFS referred to the time between initial diagnosis and recurrence or death, with follow-up censored at last contact if no event had occurred. The methylation level of top 9 CpGs located in HORMAD2 were shown in Boxplot for cg01141459, cg04046669, cg13245431, cg14509403, cg15209808, cg16686158, cg17632937, cg2184594 and cg21890667, respectively ( Figure 4A-I) . The above results illustrated the methylation level in THCA group was remarkably higher compared with control group.
| The expression of HORMAD2 was downregulated by hypermethylation in thyroid cancer
The expression of HORMAD2 was detected by qRT-PCR and Wes- was derived from follicular thyroid cancer. 18 Thyroid papillary carcinoma was the most common and the lowest degree of malignancy.
It accounts for 85% of thyroid cancer and can develop at any age.
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